A codon-defined translational program promotes RAS-driven cancer progression and drug resistance
Authors:
Open Access
- 1 January 2026
- journal article
- Published by China Engineering Science Press Co. Ltd. in Vita
Abstract
Codon usage affects translation efficiency, yet how oncogenic signaling exploits codon-selective translation remains largely unknown. Here, we uncover a codon-defined translational program as a functional output of RAS-MAPK signaling. Through integrated translational analyses, we identify a codon-defined module of genes enriched for the rare arginine codon CGA, whose translation is specifically promoted by RAS activation. These genes encode key regulators of ribosome biogenesis, RNA splicing, and cell cycle control, many previously regarded as “undruggable” drivers of tumor progression and therapeutic resistance. Mechanistically, RSK (a RAS effector kinase)-mediated phosphorylation of METTL13 at S267 enhances its stability and catalytic activity toward eEF1A K55 dimethylation, accelerating CGA decoding. Disruption of this phospho-methyl relay selectively impairs CGA translation, suppresses RAS-driven tumor growth, and overcomes both intrinsic and acquired resistance to RAS pathway inhibitors. Therapeutically, combining METTL13 inhibition with RAS signaling inhibitors achieves superior tumor suppression compared with current clinical combinations of kinase inhibitors. By defining a codon-based translational mechanism, our study reveals a previously unrecognized layer of translation-level signal interpretation, introduces a “one-handle-multiple-effector” strategy to enhance the durability of targeted cancer therapies, and establishes METTL13 as a mechanistically defined and targetable node in malignant translation control.Keywords
This publication has 64 references indexed in Scilit:
- Unlocking RAS: Finding the Right Combination Is the KeyUnited European Gastroenterology Journal, 2025
- KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancerCancer Communications, 2022
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal CancerCancer Cell, 2019
- METTL13 Methylation of eEF1A Increases Translational Output to Promote TumorigenesisCell, 2019
- Adjacent Codons Act in Concert to Modulate Translation Efficiency in YeastCell, 2016
- Modulated Expression of Specific tRNAs Drives Gene Expression and Cancer ProgressionCell, 2016
- Pausing on Polyribosomes: Make Way for Elongation in Translational ControlCell, 2015
- Optimization of Codon Translation Rates via tRNA Modifications Maintains Proteome IntegrityCell, 2015
- Codon Optimality Is a Major Determinant of mRNA StabilityCell, 2015
- A Dual Program for Translation Regulation in Cellular Proliferation and DifferentiationCell, 2014